ENZON PHARMACEUTICALS INC FILES (8-K) Disclosing Change in Directors or Principal Officers, Other Events
(Edgar Glimpses Via Acquire Media NewsEdge) Item 5.02 Departure of Directors or Certain Officers.
On October 22, 2013, Thomas F. Deuel, who previously informed Enzon
Pharmaceuticals, Inc. (the "Company") that he will not stand for re-election
when his term as a director expires at the Company's 2013 annual meeting of
stockholders, resigned as a director effective October 22, 2013. Dr. Deuel's
resignation was not, to the knowledge of the Company's executive officers, due
to any disagreement with the Company on any matter relating to the Company's
operations, policies or practices.
Item 8.01 Other Events.
On October 21, 2013, the Company and Santaris Pharma A/S ("Santaris") mutually
agreed to terminate the License and Collaboration Agreement dated July 26, 2006
between Santaris and the Company, as amended (the "License and Collaboration
Agreement"), effective as of October 21, 2013. In connection with such
termination, (i) the Company agreed that all rights, data, products and
intellectual property relating to the Company's LNA programs developed under the
license granted by Santaris under the License and Collaboration Agreement will
revert to Santaris, (ii) the Company agreed to pay an undisclosed amount to
Santaris and (iii) the Company and Santaris each agreed to release any and all
claims it may have against the other in connection with the License and
[ Back To Technology News's Homepage ]